420 related articles for article (PubMed ID: 26400665)
21. Immunolocalization of androgen receptors, estrogen alpha receptors, and estrogen beta receptors in experimentally induced canine prostatic hyperplasia.
Gallardo F; Lloreta J; García F; Moll X; Baró T; González LA; Morote J; Reventos J; Mogas T
J Androl; 2009; 30(3):240-7. PubMed ID: 19136389
[TBL] [Abstract][Full Text] [Related]
22. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
23. Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer.
Kucerova R; Bienova M; Kral M; Bouchal J; Trtkova KS; Burdova A; Student V; Kolar Z
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):91-6. PubMed ID: 24665929
[TBL] [Abstract][Full Text] [Related]
24. The therapeutic effects of docosahexaenoic acid on oestrogen/androgen-induced benign prostatic hyperplasia in rats.
Wang C; Luo F; Zhou Y; Du X; Shi J; Zhao X; Xu Y; Zhu Y; Hong W; Zhang J
Exp Cell Res; 2016 Jul; 345(2):125-33. PubMed ID: 25849092
[TBL] [Abstract][Full Text] [Related]
25. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
[TBL] [Abstract][Full Text] [Related]
26. Combination of Ligustri Lucidi Fructus with Ecliptae Herba and their phytoestrogen or phytoandrogen like active pharmaceutical ingredients alleviate oestrogen/testosterone-induced benign prostatic hyperplasia through regulating steroid 5-α-reductase.
Tao R; Liu E; Zhao X; Han L; Yu B; Mao H; Yang W; Gao X
Phytomedicine; 2022 Jul; 102():154169. PubMed ID: 35636178
[TBL] [Abstract][Full Text] [Related]
27. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer.
Rannikko S; Adlercreutz H
Prostate; 1983; 4(3):223-9. PubMed ID: 6189106
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia.
Biolchi V; Silva Neto B; Pianta DB; Koff WJ; Berger M; Brum IS
Mol Biol Rep; 2013 Mar; 40(3):2749-56. PubMed ID: 23184046
[TBL] [Abstract][Full Text] [Related]
29. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
[TBL] [Abstract][Full Text] [Related]
30. Lipid Accumulation Product (LAP) as an Index of Metabolic and Hormonal Disorders in Aging Men.
Rotter I; Rył A; Szylińska A; Pawlukowska W; Lubkowska A; Laszczyńska M
Exp Clin Endocrinol Diabetes; 2017 Mar; 125(3):176-182. PubMed ID: 27898988
[TBL] [Abstract][Full Text] [Related]
31. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue.
Brolin J; Skoog L; Ekman P
Prostate; 1992; 20(4):281-95. PubMed ID: 1376911
[TBL] [Abstract][Full Text] [Related]
33. Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes.
Stanworth RD; Kapoor D; Channer KS; Jones TH
Clin Endocrinol (Oxf); 2011 May; 74(5):624-30. PubMed ID: 21470285
[TBL] [Abstract][Full Text] [Related]
34. Association of receptor expression with prostate volume in benign prostatic hyperplasia.
Sreenivasulu K; Nandeesha H; Dorairajn LN; Rajesh NG
Indian J Pathol Microbiol; 2019; 62(1):99-102. PubMed ID: 30706868
[TBL] [Abstract][Full Text] [Related]
35. Correlation of sex hormone and androgen receptor with diabetes mellitus in elderly men.
Cao J; Li J; Hao W; Li X; Wang H; Liu L; Zhu B; Guo Z
Aging Male; 2011 Sep; 14(3):162-7. PubMed ID: 21574908
[TBL] [Abstract][Full Text] [Related]
36. 4-Nitrophenol induces Leydig cells hyperplasia, which may contribute to the differential modulation of the androgen receptor and estrogen receptor-α and -β expression in male rat testes.
Zhang Y; Piao Y; Li Y; Song M; Tang P; Li C
Toxicol Lett; 2013 Nov; 223(2):228-35. PubMed ID: 24070737
[TBL] [Abstract][Full Text] [Related]
37. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
38. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
39. The role of sex steroid hormones in benign prostatic hyperplasia.
Asiedu B; Anang Y; Nyarko A; Doku DA; Amoah BY; Santa S; Ngala RA; Asare GA
Aging Male; 2017 Mar; 20(1):17-22. PubMed ID: 28084142
[TBL] [Abstract][Full Text] [Related]
40. Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia.
Grzesiak K; Rył A; Ratajczak W; Stachowska E; Rotter I; Słojewski M; Sipak O; Walczakiewicz K; Laszczyńska M
Aging (Albany NY); 2019 Mar; 11(5):1524-1536. PubMed ID: 30867336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
